Compare Quest Diagnostics Inc (DGX) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs PayPal Holdings, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while PayPal Holdings, Inc. trades at $55 (market cap $47.01B). The key difference: PayPal Holdings, Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.52%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and PayPal Holdings, Inc. for 106 Days on average.
| DGX | PYPL | |
|---|---|---|
Market Cap | $25.06B | $47.01B |
Volume | 927,361 | 10,493,459 |
Sector | Health | Financials |
52-Week High | $247.45 | $75.75 |
52-Week Low | $173.49 | $39.08 |
Typical Hold Time | 56 Days | 106 Days |
Enterprise Value | $30.82B | $49.15B |
Dividend Yield | 1.52% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
PayPal (PYPL) trades at $55.02, up 0.75% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 10.39 and net income margin of 14.36%, while recent earnings beat expectations in two of the last three quarters. Positive sentiment is fueled by a new partnership with Meta and ongoing cost-saving initiatives under CEO Enrique Lores.
The outlook is cautiously optimistic, with a consensus price target of $56.47 offering modest upside. Key opportunities include Venmo growth and AI integration, but risks involve competitive pressures in digital payments and slowing branded checkout growth. Wall Street sentiment is mixed, with 35.71% of analysts rating it a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
